In a concession to drug companies, Senate Democrats reportedly have agreed to delay by one year—from Jan. 1, 2023 to Jan. 1, 2024—the effective date of language in the $1.9 trillion COVID-19 relief bill that might lead to 340B ceiling prices on some branded drugs being set lower than $0.01.
News organizations report that drug industry lobbyists are trying to persuade lawmakers to remove the language entirely from the relief bill. Pharma’s challenge is that the language would reduce federal Medicaid spending by $15.9 billion over 10 years—money that congressional Democrats want to use to fund state Medicaid expansion.
In a concession to drug companies, Senate Democrats reportedly have agreed to delay by one year—from Jan. 1, 2023 to Jan. 1, 2024—the effective date of language in the $1.9 trillion COVID-19 relief bill that might lead to 340B ceiling prices on some branded drugs being set lower than the drugs’ average manufacturer price (AMP).
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
